Cns Pharmaceuticals Inc (CNSP)

$5.35 -0.06 (-1.11%)
Market Cap 3.46M
Revenue (ttm) 0.00
Net Income (ttm) -14.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 13,900
Avg Vol 39,230
Day's Range N/A - N/A
Shares Out 620,000.00
Stochastic %K 7%
Beta 2.69
Analysts Strong Sell
Price Target $20.00

Company Profile

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.

Industry: Biotechnology
Sector: Healthcare
Phone: 800 946 9185
Address:
2100 West Loop South, Suite 900, Houston, United States
UCF_16
UCF_16 Feb. 3 at 4:13 PM
$CNSP
0 · Reply
youbi336
youbi336 Feb. 2 at 9:15 PM
$CNSP Hey, where's Tammy? lol
1 · Reply
Himan93
Himan93 Feb. 2 at 7:06 PM
$CNSP
0 · Reply
kl7777
kl7777 Feb. 2 at 5:38 PM
$CNSP Needs volume to go back to $15.
0 · Reply
GOGOVAXY
GOGOVAXY Feb. 2 at 10:53 AM
$CNSP
0 · Reply
Pomacanthus
Pomacanthus Jan. 31 at 7:35 PM
$CNSP Robinhood shows Friday close at 5.52
0 · Reply
NetworkNewsWire
NetworkNewsWire Jan. 30 at 8:52 PM
New Compound Could Become a Transformational Brain Cancer Pill $CNSP https://ibn.fm/0Rsxb #biomedstocks #cancer
0 · Reply
Eddie5150
Eddie5150 Jan. 30 at 6:32 PM
$CNSP avg down to 6.30. Can we send this biatch already?
0 · Reply
UCF_16
UCF_16 Jan. 30 at 12:33 PM
$CNSP Soon…
0 · Reply
youbi336
youbi336 Jan. 28 at 6:03 PM
$CNSP
0 · Reply
Latest News on CNSP
CNS Pharmaceuticals Issues Letter to Shareholders

Jan 27, 2026, 9:00 AM EST - 7 days ago

CNS Pharmaceuticals Issues Letter to Shareholders

CNS Pharmaceuticals Announces CEO Transition

Dec 17, 2025, 7:00 AM EST - 6 weeks ago

CNS Pharmaceuticals Announces CEO Transition

CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript

Nov 17, 2025, 1:17 PM EST - 2 months ago

CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript

CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 17, 2025, 8:35 AM EST - 2 months ago

CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting

Nov 10, 2025, 8:45 AM EST - 3 months ago

CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting

CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:15 AM EDT - 5 months ago

CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 15, 2025, 8:05 AM EDT - 6 months ago

CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 9:15 AM EDT - 6 months ago

CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 7 months ago

CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

CNS Pharmaceuticals Announces Reverse Stock Split

Jul 18, 2025, 8:00 AM EDT - 7 months ago

CNS Pharmaceuticals Announces Reverse Stock Split

CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment

Jul 9, 2025, 9:32 AM EDT - 7 months ago

CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

Jun 24, 2025, 9:15 AM EDT - 8 months ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

Jun 5, 2025, 8:05 AM EDT - 8 months ago

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 16, 2025, 8:05 AM EDT - 9 months ago

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

May 13, 2025, 9:35 AM EDT - 9 months ago

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

May 13, 2025, 7:00 AM EDT - 9 months ago

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

Apr 1, 2025, 8:05 AM EDT - 11 months ago

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects

Mar 25, 2025, 12:05 PM EDT - 11 months ago

CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

Mar 25, 2025, 8:00 AM EDT - 11 months ago

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

Feb 26, 2025, 9:05 AM EST - 1 year ago

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

Feb 20, 2025, 9:00 AM EST - 1 year ago

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

Feb 18, 2025, 9:00 AM EST - 1 year ago

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

Feb 10, 2025, 8:00 AM EST - 1 year ago

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

Dec 5, 2024, 9:10 AM EST - 1 year ago

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

Nov 25, 2024, 9:00 AM EST - 1 year ago

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

Nov 18, 2024, 8:55 AM EST - 1 year ago

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 15, 2024, 9:10 AM EST - 1 year ago

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

Nov 4, 2024, 9:15 AM EST - 1 year ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Nov 1, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 23, 2024, 2:50 PM EDT - 1 year ago

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

Oct 10, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

Oct 8, 2024, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

Sep 23, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

Sep 12, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

Sep 3, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Aug 27, 2024, 9:10 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

Aug 22, 2024, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 15, 2024, 8:00 AM EDT - 1 year ago

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

Jul 30, 2024, 7:00 AM EDT - 1 year ago

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

Jul 25, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

Jul 16, 2024, 9:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

Jul 3, 2024, 11:10 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 20, 2024, 8:30 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

May 16, 2024, 7:45 AM EDT - 1 year ago

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

CNS Pharmaceuticals to Present at the LSX World Congress 2024

Apr 23, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the LSX World Congress 2024

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

Apr 22, 2024, 10:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements

Apr 1, 2024, 5:00 PM EDT - 2 years ago

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements

CNS Pharmaceuticals to Present at Two Investor Conferences in April

Apr 1, 2024, 9:05 AM EDT - 2 years ago

CNS Pharmaceuticals to Present at Two Investor Conferences in April

UCF_16
UCF_16 Feb. 3 at 4:13 PM
$CNSP
0 · Reply
youbi336
youbi336 Feb. 2 at 9:15 PM
$CNSP Hey, where's Tammy? lol
1 · Reply
Himan93
Himan93 Feb. 2 at 7:06 PM
$CNSP
0 · Reply
kl7777
kl7777 Feb. 2 at 5:38 PM
$CNSP Needs volume to go back to $15.
0 · Reply
GOGOVAXY
GOGOVAXY Feb. 2 at 10:53 AM
$CNSP
0 · Reply
Pomacanthus
Pomacanthus Jan. 31 at 7:35 PM
$CNSP Robinhood shows Friday close at 5.52
0 · Reply
NetworkNewsWire
NetworkNewsWire Jan. 30 at 8:52 PM
New Compound Could Become a Transformational Brain Cancer Pill $CNSP https://ibn.fm/0Rsxb #biomedstocks #cancer
0 · Reply
Eddie5150
Eddie5150 Jan. 30 at 6:32 PM
$CNSP avg down to 6.30. Can we send this biatch already?
0 · Reply
UCF_16
UCF_16 Jan. 30 at 12:33 PM
$CNSP Soon…
0 · Reply
youbi336
youbi336 Jan. 28 at 6:03 PM
$CNSP
0 · Reply
kl7777
kl7777 Jan. 28 at 5:08 PM
$CNSP More need add at this price to go back to $15.
0 · Reply
anders_taag
anders_taag Jan. 28 at 9:23 AM
$CNSP Massive drop just before open, then recovery?
0 · Reply
jeco
jeco Jan. 27 at 9:35 PM
$CNSP
0 · Reply
NetworkNewsWire
NetworkNewsWire Jan. 27 at 5:54 PM
TinyGemsBreaks – $CNSP Issues Shareholder Letter Outlining Strategic Review and Focus on TPI 287 https://ibn.fm/Z7pqf
0 · Reply
youbi336
youbi336 Jan. 27 at 2:31 PM
$CNSP https://cnspharma.com/ir/press-releases/cns-pharmaceuticals-issues-letter-to-shareholders-50154996
0 · Reply
Aliuse
Aliuse Jan. 27 at 4:35 AM
$CNSP buying it before FOMO kicks in
0 · Reply
Aliuse
Aliuse Jan. 27 at 12:33 AM
$CNSP something major is coming
0 · Reply
Aliuse
Aliuse Jan. 26 at 11:29 PM
$CNSP average analyst price target
0 · Reply
Pomacanthus
Pomacanthus Jan. 26 at 8:00 PM
$CNSP vwap fail, theres always tomorrow, next week, next month….
0 · Reply
Pomacanthus
Pomacanthus Jan. 26 at 7:29 PM
$CNSP somebody give that momentum algo a kick in ass we need 6.40 to fly. 😎
0 · Reply
Aliuse
Aliuse Jan. 26 at 6:52 PM
$CNSP FDA news coming soon
0 · Reply
Balespur
Balespur Jan. 26 at 4:57 PM
$CNSP back down to zero volume, which means im back in to ride it up again.
0 · Reply